Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TGM1 | P22735 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514525 | 0.89 | GPR119 (0.74) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL4513931 | 0.88 | GPR119 (0.61) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL4503463 | 0.88 | GPR119 (0.61) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL4504686 | 0.87 | GPR119 (0.69) | GPR119TGFBR1 | |
| Hydrochloric Acid SCHEMBL4507662 | 0.87 | GPR119 (0.60) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL13757780 | 0.86 | GPR119 (0.59) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL13757785 | 0.86 | GPR119 (0.56) | GPR119TGFBR1MEN1KMT2A | |
| SCHEMBL27712492 | 0.85 | GFER (0.48) | GPR119GFER | |
| SCHEMBL7366692 | 0.84 | GPR119 (0.59) | GPR119TGFBR1 | |
| SCHEMBL4516799 | 0.84 | ABL1 (0.58) | GPR119TGFBR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1909791-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | GPR119 1/4885TGFBR1 834/4885MEN1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.